NCT02724332View on ClinicalTrials.gov

Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC

PHASE1CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

December 31, 2015

Conditions
Hepatocellular CarcinomaRapamycin
Interventions
DRUG

Rapamycin

2mg,po,bid

Trial Locations (1)

200438

Eastern hepatobilliary surgery hospital, Shanghai

All Listed Sponsors
lead

Eastern Hepatobiliary Surgery Hospital

OTHER

NCT02724332 - Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC | Biotech Hunter | Biotech Hunter